Arcus Capital Partners LLC Has $76,000 Holdings in Elutia Inc. (NASDAQ:ELUT)

Arcus Capital Partners LLC boosted its holdings in shares of Elutia Inc. (NASDAQ:ELUT) by 100.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,000 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Arcus Capital Partners LLC’s holdings in Elutia were worth $76,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in shares of Elutia by 50.5% during the 2nd quarter. Renaissance Technologies LLC now owns 53,616 shares of the company’s stock valued at $266,000 after acquiring an additional 18,000 shares during the last quarter. Perkins Capital Management Inc. bought a new position in shares of Elutia in the first quarter valued at approximately $2,512,000. AIGH Capital Management LLC boosted its holdings in shares of Elutia by 288.8% during the 2nd quarter. AIGH Capital Management LLC now owns 1,697,316 shares of the company’s stock worth $8,419,000 after buying an additional 1,260,750 shares during the period. Finally, Nantahala Capital Management LLC grew its stake in Elutia by 8.8% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,795,697 shares of the company’s stock valued at $8,907,000 after buying an additional 145,697 shares during the last quarter. 74.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price target on shares of Elutia in a research report on Friday, September 6th.

Elutia Price Performance

NASDAQ:ELUT opened at $3.80 on Tuesday. Elutia Inc. has a one year low of $1.39 and a one year high of $5.24. The company has a fifty day moving average price of $3.76 and a 200 day moving average price of $3.67. The stock has a market cap of $129.43 million, a P/E ratio of -1.33 and a beta of 0.76.

About Elutia

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.